JPRN-UMIN000002579
Recruiting
Phase 2
Clinical study evaluating efficacy of Nilotinib in CML patients - Clinical study evaluating efficacy of Nilotinib in CML patients
ara Hospital Kinki University School Of Medicine0 sites20 target enrollmentOctober 4, 2009
ConditionsChronic myelogenous leukemia
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Chronic myelogenous leukemia
- Sponsor
- ara Hospital Kinki University School Of Medicine
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients suspected in accelerated phase(AP) or in blast crisis(BC). 2\) Confirmed the expression of T315I mutation at genetic screening. 3\) Previously treated with any other agents or therapy for CML, other than Hydroxyurea, Interferon\-alfa, and Imatinib. 4\) History of a invasive double cancer within 5 years before. 5\) Presence of serious or uncontrolled concomitant disease. 6\) Pregnancy or possibility of pregnancy positive. 7\) Women with lactation status or patients who have willing of pregnancy. 8\) Patients suffering mental disorder or psychotic symptom.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM) - Nilotinib in the Treatment of c-KIT Mutated Melanoma (NICAM)c-KIT mutated advanced acral or mucosal melanomaMedDRA version: 10 Level: LLT Classification code 10025654 Term: Malignant melanoma of sites other than skinMedDRA version: 10 Level: LLT Classification code 10000583 Term: Acral lentiginous melanomaEUCTR2009-012945-49-GBRoyal Marsden Hosptial Foundation Trust29
Not yet recruiting
Not Applicable
Efficacy and safety evaluation of nilotinib as primary treatment in newly diagnosed Philadelphia chromosome positive(Ph+) chronic myeloid leukemia(CML) patientsDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0000615Seoul National University Hospital114
Completed
Not Applicable
Clinical trial on the efficacy and safety of Nobilex 90 to fatty liverJPRN-UMIN000034957Southern Knights' Laboratory Co., Ltd.40
Active, not recruiting
Phase 1
An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-PCRChronic Myelogenous Leukemia in Chronic PhaseMedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaEUCTR2009-012616-40-FRovartis Pharma Services AG192
Active, not recruiting
Not Applicable
An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-PCRilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-PCRMedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaEUCTR2009-012616-40-GBovartis Pharma Services AG192